Get the Stockscreener App
2.05
5.09%
-0.11
OncoCyte Corporation Stock (OCX) Latest News
Oncocyte corp investor Patrick Smith buys $1,839 in shares By Investing.com - Investing.com
OncoCyte stock hits 52-week low at $1.92 amid market challenges - MSN
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock - Investing.com India
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock By Investing.com - Investing.com Australia
OncoCyte (STU:7OC0) PS Ratio : 47.04 (As of Jan. 15, 2025) - GuruFocus.com
OncoCyte Co. (NASDAQ:OCX) Shares Bought by Geode Capital Management LLC - Defense World
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte Corporation (NASDAQ: OCX) Enters Amendment to Lease Agreement with Induce Biologics USA, Inc. and Cushing Ventures, LLCOn January 2, 2025, Oncocyte Corporation announced in a Form 8-K filing that it has entered into an Amendment to a - Defense World
Oncocyte Corp amends lease agreement, sets expiration date By Investing.com - Investing.com Nigeria
Oncocyte Corp amends lease agreement, sets expiration date - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - Markets Insider
Oncocyte names Dr. Paul Billings as Consulting CMO - Investing.com India
Oncocyte Taps Harvard-Trained Diagnostics Veteran Dr. Paul Billings as Chief Medical Officer - StockTitan
Dr. Paul Billings Appointed Consulting Chief Medical Officer at OncoCyte - citybiz
Medicare expands coverage for kidney transplant test By Investing.com - Investing.com Australia
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - The Manila Times
OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com - Defense World
Oncocyte's VitaGraft Kidney Test Gains Expanded Medicare Coverage for Early Rejection Detection - StockTitan
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World
Oncocyte corp investor Patrick Smith buys $192,166 in stock By Investing.com - Investing.com Nigeria
OncoCyte stock hits 52-week low at $1.97 amid market challenges - Investing.com Nigeria
Oncocyte corp director Arno Andrew buys $26,350 in shares - Investing.com India
StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com - Defense World
Oncocyte to Participate in 'J.P. Morgan Week” and Host Investor Meetings - The Manila Times
Oncocyte corp CFO James Andrea acquires $45,800 in stock - Investing.com India
Oncocyte corp CFO James Andrea acquires $45,800 in stock By Investing.com - Investing.com Canada
Oncocyte Corp to Meet Investors at J.P. Morgan Healthcare Conference 2025 - StockTitan
OCXOncocyte Corporation Latest Stock News & Market Updates - StockTitan
OncoCyte stock hits 52-week low at $1.98 amid market challenges - Investing.com Nigeria
OncoCyte stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Oncocyte study shows potential for non-invasive brain tumor diagnosis By Investing.com - Investing.com Nigeria
Oncocyte study shows potential for non-invasive brain tumor diagnosis - Investing.com
OncoCyte announces publication of DetermaCNI assay data - TipRanks
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study - The Manila Times
Oncocyte's Brain Cancer Liquid Biopsy Test Shows Breakthrough 83% Detection Rate in Clinical Study - StockTitan
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms - The Manila Times
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):